Before Telesurgery Comes to Your OR Who Owns the Backup Plan

On September 24, 2026, FDA released draft guidance for premarket submissions involving certain robotically assisted surgical devices. The document addresses recommended nonclinical testing, clinical data and labeling intended to support consistent review of these systems.

The guidance is not final and does not authorize remote surgery in the United States. But its arrival alongside growing international experience with telesurgery makes one thing clear: the conversation is moving from whether remote surgical capability is possible to what must be proven before it becomes routine.

What the FDA document does

FDA defines robotically assisted surgical devices as teleoperated, software-controlled systems that help qualified practitioners position and control one or more surgical instruments during open, minimally invasive or endoluminal procedures.

The draft guidance communicates FDA's current recommendations for the evidence and labeling manufacturers should include in premarket submissions. It is nonbinding and open for public comment through November 24, 2026.

For manufacturers, the document is a regulatory roadmap. For surgical professionals, it is a reminder that the safety of a robotic system depends on more than precise instrument motion. It also depends on the environment, training, workflow, human factors and contingency plans surrounding the technology.

Telerobotic surgery is advancing outside routine US practice

Remote robotic procedures have already been performed internationally, including cardiac, urologic, gynecologic, thoracic and stroke interventions. Advocates see the potential to bring specialized care to patients who live far from experienced surgeons or comprehensive treatment centers.

However, no surgical robot is currently authorized for routine remote procedures in the United States. The technology must address not only surgical performance but also latency, network reliability, cybersecurity, licensing, credentialing, reimbursement and emergency response.

The bedside team cannot be an afterthought

Telesurgery is often described through the person operating the console. But patient safety will also depend on the clinicians physically present with the patient.

If the connection degrades, the robot faults, bleeding occurs or an open conversion becomes necessary, the remote surgeon cannot physically enter the field. The bedside team must be able to assess the situation, communicate clearly, secure the device and escalate or convert according to a rehearsed plan.

That means readiness is not achieved by installing a robot and verifying internet speed. It requires competency validation for the entire team, defined decision authority and resources for the worst credible failure.

Questions OR leaders should ask before remote capability

What network performance and redundancy are required, and how are they monitored during the case?

What happens after a brief delay, a complete connection loss or conflicting system data?

Who at the bedside has authority to stop the procedure?

Which surgeon must be physically available, and how quickly can that person intervene?

Can the team undock and convert safely without the remote operator?

How will credentialing and licensure work across facilities or state lines?

What data leave the OR, where are they stored and how are they protected?

How will near misses and device-related events be reported and reviewed?

Why surgical professionals should join the conversation now

The professionals who circulate, scrub, position, troubleshoot, process instruments and respond to emergencies understand hazards that may not be obvious in a development lab. Their experience belongs in purchasing decisions, simulations, policy development and regulatory feedback.

The strongest question is not whether a remote surgeon can move the instruments. It is whether the complete system can protect the patient when conditions stop being ideal. Before telesurgery reaches the OR, someone must own the backup plan—and the entire team must know it.

U.S. Food and Drug Administration. (September 24, 2026). “Robotically-Assisted Surgical Devices—Premarket Submissions.” Draft guidance. Cite for the proposed submission recommendations and comment deadline. FDA

U.S. Food and Drug Administration. “Robotic Medical Devices.” Cite separately for FDA’s discussion of remote teleoperation. FDA

MedTech Dive. (September 23, 2026). “Telerobotic surgery is advancing around the world. Will the US embrace it?.” Use as reporting for the international examples and US implementation questions, rather than as the source for what FDA’s draft says.